|
Reslizumab improves asthma control, symptoms, lung function
Healio “Intravenous reslizumab [Cinqair, Teva Respiratory] 3.0 mg/kg provided improvements in lung function, asthma symptoms, and quality of life for patients with inadequately controlled asthma and elevated blood eosinophils (? 400 cells/µL) that were … |
View full post on asthma – Google News